Name | Value |
---|---|
Revenues | 123.8K |
Cost of Revenue | 13.0K |
Gross Profit | 110.8K |
Operating Expense | 2,155.2K |
Operating I/L | -2,044.4K |
Other Income/Expense | -2.6K |
Interest Income | 0.0K |
Pretax | -2,047.1K |
Income Tax Expense | 0.0K |
Net Income/Loss | -2,047.1K |
PetVivo Holdings, Inc. is a biomedical device company specializing in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its primary revenue-generating product, Spryng, is a veterinarian-administered, intraarticular injection designed for the management of lameness and joint afflictions, including osteoarthritis in dogs and horses. The company's product pipeline includes 17 therapeutic devices for veterinary and human clinical applications, positioning PetVivo as a key player in the animal healthcare industry.